Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate

BMC Clinical Pharmacology

Quan Dong Nguyen⁵  Peter A Campochiaro⁴  James T Handa⁴  Jai Balkissoon¹  Richard Rivers²  J Kevin Donahue³  Gulnar Hafiz⁴  Elizabeth Van Anden⁴  Syed M Shah⁴  Yasir J Sepah⁴  Diana V Do⁵  Mohamed A Ibrahim⁴ 

[1]OxiGene, Inc., South San Francisco, California, CA, USA

[2]Department of Anesthesia, Johns Hopkins University School of Medicine, Baltimore, MD, USA

[3]Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA

[4]Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Maumenee 745, Baltimore, MD 21287, USA

[5]Stanley M. Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE, USA

关键词: VDA;    Vascular disrupting agents;    CA4P;    Combretastatin A-4 Phosphate;    Retinal degeneration;    Ocular pharmacology;    Neovascularization;    Angiogenesis;   

Others  :  860664
DOI  :  10.1186/2050-6511-14-7

 received in 2012-02-06, accepted in 2013-01-02,  发布年份 2013

【 摘 要 】

Background

This study was designed to assess the safety, tolerability, and efficacy of intravenous infusion of CA4P in patients with neovascular age-related macular degeneration (AMD).

Methods

Prospective, interventional, dose-escalation clinical trial. Eight patients with neovascular AMD refractory to at least 2 sessions of photodynamic therapy received CA4P at a dose of 27 or 36 mg/m² as weekly intravenous infusion for 4 consecutive weeks. Safety was monitored by vital signs, ocular and physical examinations, electrocardiogram, routine laboratory tests, and collection of adverse events. Efficacy was assessed using retinal fluorescein angiography, optical coherence tomography, and best corrected visual acuity (BCVA).

Results

The most common adverse events were elevated blood pressure (46.7%), QTc prolongation (23.3%), elevated temperature (13.3%), and headache (10%), followed by nausea and eye injection (6.7%). There were no adverse events that were considered severe in intensity and none resulted in discontinuation of treatment. There was reduction of the excess foveal thickness by 24.15% at end of treatment period and by 43.75% at end of the two-month follow-up (p = 0.674 and 0.161, respectively). BCVA remained stable throughout the treatment and follow-up periods.

Conclusions

The safety profile of intravenous CA4P was consistent with that reported in oncology trials of CA4P and with the class effects of vascular disruptive agents; however, the frequency of adverse events was different. There are evidences to suggest potential efficacy of CA4P in neovascular AMD. However, the level of systemic safety and efficacy indicates that systemic CA4P may not be suitable as an alternative monotherapy to current standard-of-care therapy.

Trial registration

ClinicalTrials.gov NCT01570790.

【 授权许可】

   
2013 Ibrahim et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Hu E, Ko R, Koda R, Rosen P, Jeffers S, Scholtz M, Muggia F: Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies. Cancer Chemother Pharmacol 1990, 26(5):359-364.
• [2]Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, Lorusso PM: Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005, 11(2 Pt 1):416-420.
• [3]Duncan DD, Lemaillet P, Ibrahim M, Nguyen QD, Hiller M, Ramella-Roman J: Absolute blood velocity measured with a modified fundus camera. J Biomed Opt 2010, 15(5):056014.
• [4]Siemann DW, Chaplin DJ, Walicke PA: A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009, 18(2):189-197.
• [5]Griggs J, Skepper JN, Smith GA, Brindle KM, Metcalfe JC, Hesketh R: Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am J Pathol 2002, 160(3):1097-1103.
• [6]Nambu H, Nambu R, Melia M, Campochiaro PA: Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003, 44(8):3650-3655.
• [7]Cooney MM, Savvides P, Agarwala S, Wang D, Flick S, Bergant S, Bhakta S, Lavertu P, Ortiz J, Remick S: Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J Clin Oncol (Meet Abstracts) 2006, 24(18_suppl):5580.
• [8]Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, et al.: A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002, 62(12):3408-3416.
• [9]Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, et al.: Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003, 21(23):4428-4438.
• [10]Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM: Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003, 21(15):2815-2822.
• [11]Martel CL, Ebrahimi B, Horns RC, Upadhyaya GH, Vakil MJ, Yeon CH, Bosserman LD, Presant CA: Incidence of bevacizumab (BE) related toxicities: Association of hypertension (HTN) and proteinuria (PTN), a BE toxicity syndrome (BETS). J Clin Oncol 2005, 23(16):744s.
• [12]Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS: Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005, 112(6):1035-1047.
• [13]Schmid-Kubista KE, Krebs I, Gruenberger B, Zeiler F, Schueller J, Binder S: Systemic bevacizumab (avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-study. Br J Ophthalmol 2009, 93(7):914-919.
• [14]Geitzenauer W, Michels S, Prager F, Rosenfeld PJ, Kornek G, Vormittag L, Schmidt-Erfurth U: Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort study. Retina 2008, 28(10):1375-1386.
• [15]Spaide RF, Koizumi H, Freund KB: Photoreceptor outer segment abnormalities as a cause of blind spot enlargement in acute zonal occult outer retinopathy–complex diseases. Am J Ophthalmol 2008, 146(1):111-120.
• [16]Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, Levine SL, DeCaro K, Buchter C, Taylor A, et al.: Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004, 10(1):96-100.
• [17]Griggs J, Metcalfe JC, Hesketh R: Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2001, 2(2):82-87.
• [18]Koh DM, Blackledge M, Collins DJ, Padhani AR, Wallace T, Wilton B, Taylor NJ, Stirling JJ, Sinha R, Walicke P, et al.: Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009, 19(11):2728-2738.
• [19]Patterson DMRGJS, Serradell N, Rosa E, Bolos J: Combretastatin A-4 phosphate: Vascular disrupting agent oncolytic treatment of age-related macular degeneration. Drugs future 2007, 32(12):1025-1032.